Nasdaq
$87.20▼ 0.58%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.46BShares out 62.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 1d agoAfter-hours26.10.24 06:004Ownership#●●●
Kodiak Sciences Inc.
Kodiak Sciences Inc. insider John A. Borgeson filed a Form 4 report regarding changes in beneficial ownership of securities as of October 21, 2026. This filing serves as a standard disclosure of insider transactions and does not indicate any significant changes to the company's financial position or corporate control.…more
$87.20-0.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:21144Ownership
Kodiak Sciences Inc.
Kodiak Sciences Inc. insider John A. Borgeson has filed an SEC Form 144 to report a proposed sale of company stock. This is a standard filing disclosing an insider's plan to dispose of shares.…more
$87.20-0.58%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 06:19S-3ASROffering
Kodiak Sciences Inc.
Kodiak Sciences has entered into a distribution agreement with J.P. Morgan to sell up to $350 million of its common stock from time to time. This S-3ASR filing establishes a shelf registration statement for the potential future offering of common stock, preferred stock, debt securities, and warrants.…more
$87.20-0.58%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoAfter-hours26.10.21 06:34Bullish#●●●#●●●
Kodiak Sciences Files Shelf Prospectus For Offering
Kodiak Sciences has filed a shelf prospectus with the SEC for a potential offering. While the specific size remains undisclosed, the move signals potential future equity dilution for shareholders.…more
$87.20-0.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.28Regular26.09.28 23:05
●●●●●●●● ●●●●● ●●●●●●
Kodiak Sciences announced that its wet age-related macular degeneration drug candidates showed non-inferior vision gains compared to Regeneron's Eylea in Phase 3 trials. The company plans to submit a biologics license application for the drug in the fourth quarter of 2026.…more
$87.20-0.58%vs prev closeShareBenzinga - 9.28Pre-market26.09.28 19:34
●●●●●●●● ●●●●● ●●●●●●
Kodiak Sciences met primary endpoints in its Phase 3 DAYBREAK study, demonstrating non-inferiority of its treatments compared to aflibercept. The company plans to submit a biologics license application in the fourth quarter of 2026.…more
$87.20-0.58%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report